Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial [0.03%]
用于膀胱保存的选择性手术之前的特瑞普利单抗联合吉西他滨和顺铂新辅助治疗肌层浸润性膀胱癌：一项II期临床研究
Zhou Tong,Guanghou Fu,Feng Zhou et al.
Zhou Tong et al.
Purpose: To evaluate the safety and efficacy of GP regimen in combination with immune checkpoint inhibitor sintilimab as neoadjuvant therapy for MIBC patients and the feasibility of the following selective bladder sparing...
Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-Invasive Imaging Application [0.03%]
理解免疫细胞对肿瘤低氧的适应性以最大化免疫治疗疗效：生物学和无创成像应用
Taerim Oh,Minwoo Kim,Gi-Sue Kang et al.
Taerim Oh et al.
It is extensively documented that tumor hypoxia contributes to the failure of chemotherapy and radiotherapy. Recent evidence suggest hypoxia is also closely involved in the resistance to immunotherapy. In this review, we highlight how immun...
RASSF4 Suppresses Gastric Tumor Growth through Activation of Chk2-p53 Signaling Axis [0.03%]
RASSF4通过激活Chk2-p53信号轴抑制胃肿瘤生长
Soon-Ki Park,Min-Ju Kang,Kyung-Phil Ko et al.
Soon-Ki Park et al.
Purpose: Ras association domain family 4 (RASSF4) is a putative tumor suppressor that is frequently inactivated in multiple human cancers. However, its candidacy as a suppressor in gastric tumorigenesis remains undefined....
Deciphering the Risk of Developing Lung Cancer After the Diagnosis of Gastric Cancer with Genetic Evidence: A European and East Asian Populations-Based Mendelian Randomization Analysis [0.03%]
基于欧洲和东亚人群的孟德尔随机化分析解锁胃癌诊断后发生肺癌的风险的遗传证据
Jiansheng Chen,Aiming Zeng,Yunzhe Yu et al.
Jiansheng Chen et al.
Purpose: Lung cancer is frequently observed as a second primary malignancy following gastric cancer, yet the genetic causality between them remains uncertain. This study aims to evaluate the causal relationship between ga...
Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+ISH+ and HER2 3+ in HER2-Positive Breast Cancer [0.03%]
乳腺癌中HER2 2+ISH+和HER2 3+对新辅助抗HER2治疗的反应差异
Lingjun Ma,Ran Zheng,Lingyun Xu et al.
Lingjun Ma et al.
Purpose: Dual anti-HER2 drugs has become the standard regimen for neoadjuvant systematic treatment (NST) to HER2-positive breast cancer patients. However, the efficacy varies greatly among patients with different HER2 pro...
Cost-Effectiveness Analysis of Daratumumab Monotherapy and Subsequent Therapies in Heavily Treated Relapsed/Refractory Multiple Myeloma: A Feasible Methodology using a Korean Nationwide Population Cohort [0.03%]
利拉鲁肽与甘舒霖在新诊断的成人2型糖尿病患者中联合二甲双胍和/或磺脲类药物治疗时的成本效果分析：一项针对韩国全国人群队列研究的方法学研究
Sung-Soo Park,Suein Choi,Seungpil Jung et al.
Sung-Soo Park et al.
Purpose: High-cost novel therapies for multiple myeloma (MM) require evaluation of efficacy and cost-effectiveness. Materials and methods: ...
Comparison of Long-term Oncological Outcome of Sentinel Lymph Node Mapping Methods (Dye-Only versus Dye and Radioisotope) in Breast Cancer Patients Following Neoadjuvant Chemotherapy [0.03%]
新辅助化疗乳腺癌患者前哨淋巴结示踪（单染料与双示踪剂）长期肿瘤学结果的比较研究
Jinyoung Byeon,Changjin Lim,Eunhye Kang et al.
Jinyoung Byeon et al.
Purpose: Sentinel lymph node biopsy (SLNB) using dye and isotope (DUAL) is recommended over the dye-only (DYE) method after neoadjuvant chemotherapy (NCT) due to potentially lower false-negative rates. However, the long-t...
Spatial Transcriptomic Landscape of Brain Metastases from Triple-Negative Breast Cancer: Comparison of Primary Tumor and Brain Metastases Using Spatial Analysis [0.03%]
三阴性乳腺癌脑转移的空间转录组景观：使用空间分析法比较原发灶和脑转移灶的区别
Jihwan Yoo,Inho Park,Hyun Jung Kim et al.
Jihwan Yoo et al.
Purpose: Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer, with approximately 30% of patients eventually developing brain metastases (BM), which result in poor outcomes. An unders...
The Impact of Obesity on Treatment Outcomes in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Receiving CDK 4/6 Inhibitors [0.03%]
激素受体阳性HER2阴性转移性乳腺癌接受CDK4/6抑制剂治疗的患者肥胖对其疗效的影响研究
Yoo Bin Jung,Hee Kyung Ahn,Hyun-Young Shin et al.
Yoo Bin Jung et al.
Purpose: Guidelines from the aromatase inhibitor era for early breast cancer (EBC) treatment recommend maintaining a body mass index (BMI) below 25. In the current era of CDK 4/6 inhibitors, now standard in metastatic bre...
Survival Rates of Patients with Gastric Cancer According to Age and Sex: A Large-Scale Study Using Data from 14,739 Patients [0.03%]
基于14739例胃癌患者的大样本研究不同年龄和性别患者的生存率分析
Yonghoon Choi,Nayoung Kim,Ji Hyun Kim et al.
Yonghoon Choi et al.
Purpose: The male predominance in the incidence of gastric cancer (GC) is established; however, sex differences in the prognosis of GC remain controversial. As such, this study analyzed the prognosis of patients with GC b...